- Time:
The success of cell-based immunotherapies is transforming precision medicine, and the clinical potential has biopharmaceutical researchers brimming with excitement. For instance, CAR-T therapies employed for certain leukemias and lymphomas have led to complete remission for more than 70% of patients—doubling the success rates of current gold standard treatments. Yet, new successes are often met with unique challenges that need to be overcome for innovative technologies to keep moving forward. For cell therapies, the difficulties of defining and characterizing highly complex living cell products, such as heterogenous re-engineered T cells, is of paramount concern for investigators. Having the ability to drive better outcomes by profiling the complete function of each cell would be a significant advantage for bioengineers—a challenge the IsoPlexis single-cell proteomic system has been designed to address. Join us for the exciting new GEN webinar, where our presenters will discuss the evolution of the cell therapy industry and describe how the IsoPlexis systems have begun to redefine what is possible through the ability to stratify patient response to novel immunotherapy regimens.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
James R. Heath, PhD
President & Professor
Institute for Systems Biology
Jonathan Chen, MS
Director of New Collaborations
IsoPlexis
